Since RVX-208 increases ApoA-I by production the Phase 1b/2a trial also examined early markers for ApoA-I production and reverse cholesterol transport such as pre-beta-HDL and Alpha1-HDL. Approximately half of the subjects had low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease.
"Showing in the Phase 1b/2a trial that we met the primary endpoint of increasing plasma ApoA-I in a safe and tolerable way is a huge milestone for Resverlogix," stated Donald J. McCaffrey, President CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey.
In addition to successfully completing the Phase 1b/2a trial, Resverlogix has also completed two arms of a Phase 1 BE (bio-equivalency) study for RVX-208 with the final arm being scheduled for completion in the end of the third quarter. The Phase 1 BE trial is a program designed to show that the newly formed capsule version of RVX-208 is equivalent to the earlier powder in a bottle version that has been used in all trials to date.
In unrelated news Mr. Kelly McNeill, Resverlogix CFO, will be leaving his current position effective September 18, 2009 and returning to Winnipeg for
|SOURCE Resverlogix Corp.|
Copyright©2009 PR Newswire.
All rights reserved